Once weekly diabetes treatment promising in first Phase III trial

A new long-acting incretin mimetic under development for adjunctive therapy of type II diabetes has met its primary end point in a Phase III study.

by
Taspoglutide, like other GLP-1 analogues, is administered by subcutaneous injection.
Taspoglutide, like other GLP-1 analogues, is administered by subcutaneous injection.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package